Back to search

Article

Lead-in therapy targeting PD1 and/or LAG3 imposes distinct immune phenotypes in first-line treatment of metastatic melanoma

2025-11-06

Abstract excerpt

Simultaneous blockade of lymphocyte activation gene-3 (LAG-3) and programmed-death-1 (PD-1) pathways enhance anti-tumor activity in patients with melanoma. It is not known if this immunotherapy induces unique immune modulation or how this may relate to clinical outcomes, compared to the single modalities. We conducted a randomized three-arm phase 2 trial ( NCT03743766 ) in advanced melanoma comparing lead-in trea...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
c73cdb2c-7e2c-59a5-b32a-577c8c5fd14c
DOI
10.1101/2025.11.04.25339499
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Lead-in therapy targeting PD1 and/or LAG3 imposes distinct immune phenotypes in first-line treatment of metastatic melanomaDOI 10.1101/2025.11.04.25339499
LAG3-PD1 or CTLA4-PD1 Inhibition in Advanced Melanoma: Indirect Cross Comparisons of the CheckMate-067 and RELATIVITY-047 TrialsSemantic proximity
LAG ‐3 transcriptomic expression patterns across malignancies: Implications for precision immunotherapeuticsSemantic proximity
Nivolumab plus relatlimab in patients with previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 studySemantic proximity
Long-term survival after neoadjuvant low-dose ipilimumab plus high-dose nivolumab in resectable stage III melanoma: the 5-year survival-update and biomarker analysis from the PRADO-trialSemantic proximity
Nivolumab and Ipilimumab in Metastatic Melanoma Are Associated with Distinct Immune Landscape Changes and Response-Associated ImmunophenotypesSemantic proximity
PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumorsSemantic proximity
Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcome.Semantic proximity
The pathway ahead in melanoma trials.Semantic proximity
PD-1/LAG-3 Dysfunctionality Signatures in Human CancersSemantic proximity
Systemic immune dysfunction in cancer patients driven by IL6 and IL8 induction of an inhibitory receptor module in peripheral CD8 <sup>+</sup> T cellsSemantic proximity
Multiomics analysis reveals a Type III driven immune response in immunotherapy-induced toxicity in melanoma and identifies potential new therapeutic targetsSemantic proximity
Gene of the month: lymphocyte-activation gene 3 (LAG-3)Semantic proximity
Select a neighboring publication to make it the new centre.